Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Altering Cancer Metabolism Helps Treatments Attack Tumors

By Cancer Research UK | November 30, 2018

Restricting the ability of cancer cells to metabolize sugar could make oncolytic viruses more effective at attacking them, suggests a study published in the journal Cancer Research.

Viruses that are trained to attack cancer cells – known as oncolytic viruses – can kill tumors without affecting healthy cells nearby. They normally work by invading the cells, multiplying, and destroying the tumor from inside. They are currently being tested in clinical trials.

In this new study, a team of scientists exposed lung, ovarian and colon cancer cells, and mouse models, to conditions similar to those in the human body, and investigated how manipulating cell metabolism can make cancer more vulnerable to oncolytic viruses.

In the lab, scientists usually keep cells at the perfect temperature and provide them with lots of glucose, as it’s easier to grow and store them this way. In this study, the researchers changed the lab conditions to make them reflect what actually happens in the human body, where sugar levels are much lower.

They found that oncolytic viruses worked better when less glucose was available. To investigate whether they could make the virus work even harder, the researchers then used a drug to restrict the cancer cells’ ability to metabolize sugar – its energy source – to see if this optimized the virus’s cancer killing capability. They found that reducing sugar levels allowed the virus to multiply much faster, making treatment more effective and destroying cancer quicker.

Arthur Dyer, lead author and Cancer Research UK-funded Ph.D. student from the University of Oxford, said: “Our research in the lab showed that restricting the amount of sugar available to cancer cells makes these cancer-attacking oncolytic viruses work even better. We already know that this virus is effective against cancer – and this sugar-starving technique is a way to make it even better.”

This approach may also improve how potential cancer drugs are investigated in the lab.

Arthur Dyer added: “When studying any kind of drug in the lab, we keep the cells in very high sugar conditions – it’s a bit like soaking them in Lucozade. But this doesn’t reflect the conditions that these cells would be exposed to in the body, which are normally much poorer – in cancer they’re even worse because tumors typically have poor circulation. Our approach is more realistic in mimicking the conditions in the human body, which ultimately may help us to better predict how patients will respond to drugs well before any trials are planned.”

However, the researchers caution that their early findings should not be misinterpreted by patients who are looking to optimize treatments.

Professor Len Seymour, Cancer Research UK-funded study author from the University of Oxford, explains: “It’s important to remember that changing your diet is not enough to starve cancer cells of sugar. A lot of people think that carbohydrates are bad, but that’s not the case – we need them, and cutting out sugar won’t cure cancer. Because cancer gobbles up glucose so quickly, the cells are very vulnerable to attack from a drug that targets the sugar pathway. The same effect cannot be achieved by eliminating sugar from your diet.”

Dr. David Scott, Cancer Research UK’s director of discovery research, said: “By making treatments work more effectively, we hope that patients will be able to see positive results faster than before. The next step is to test whether this approach works in clinical trials, and to find out which cancers respond best.”

The team are aiming to test their glucose-limiting approach to improving oncolytic virus treatment in clinical trials to assess whether it could be successfully implemented in cancer patients.


Filed Under: Oncology

 

Related Articles Read More >

AP Biosciences charts course for safer CD137 bispecifics with its T-cube platform
Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
Why smaller, simpler molecular glues are gaining attention in drug discovery
Technology background. Big data concept. Binary computer code. Vector illustration.
COTA Healthcare announces AI milestone in real-world oncology data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE